C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 121 filers reported holding C4 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,067 | -47.7% | 2,186,459 | -22.7% | 0.00% | 0.0% |
| Q2 2023 | $7,780 | -13.8% | 2,828,605 | -1.6% | 0.00% | 0.0% |
| Q1 2023 | $9,029 | -47.7% | 2,875,374 | -1.7% | 0.00% | -66.7% |
| Q4 2022 | $17,259 | -99.9% | 2,925,253 | -1.3% | 0.00% | -25.0% |
| Q3 2022 | $25,996,000 | -21.3% | 2,964,056 | -32.4% | 0.00% | 0.0% |
| Q2 2022 | $33,049,000 | -68.9% | 4,383,163 | +0.1% | 0.00% | -63.6% |
| Q1 2022 | $106,195,000 | -19.3% | 4,377,372 | +7.2% | 0.01% | -8.3% |
| Q4 2021 | $131,530,000 | -25.6% | 4,084,798 | +3.2% | 0.01% | -29.4% |
| Q3 2021 | $176,832,000 | +31.8% | 3,957,743 | +11.6% | 0.02% | +41.7% |
| Q2 2021 | $134,137,000 | +72.9% | 3,544,837 | +69.0% | 0.01% | +50.0% |
| Q1 2021 | $77,598,000 | +57.1% | 2,097,809 | +37.1% | 0.01% | +60.0% |
| Q4 2020 | $49,381,000 | – | 1,530,042 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $14,402,000 | 1.72% |
| Soleus Capital Management, L.P. | 1,441,513 | $12,642,000 | 1.72% |
| Nextech Invest Ltd. | 375,857 | $3,296,000 | 1.06% |
| RTW INVESTMENTS, LP | 2,819,472 | $24,727,000 | 0.57% |
| ArrowMark Colorado Holdings LLC | 5,091,975 | $44,657,000 | 0.55% |
| WASATCH ADVISORS LP | 5,934,476 | $52,045,000 | 0.36% |
| HARBOR CAPITAL ADVISORS, INC. | 25,470 | $223,000 | 0.20% |
| Perceptive Advisors | 766,231 | $6,720,000 | 0.20% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 606,721 | $5,321,000 | 0.08% |
| Virtus ETF Advisers LLC | 19,305 | $169,000 | 0.07% |